

Giulia Carla C Marchetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4549246/publications.pdf>

Version: 2024-02-01

164
papers

5,262
citations

101496

36
h-index

102432

66
g-index

169
all docs

169
docs citations

169
times ranked

6743
citing authors

#	ARTICLE	IF	CITATIONS
1	Female gender is associated with long COVID syndrome: a prospective cohort study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 611.e9-611.e16.	2.8	230
2	Persistence of High Peripheral Activated CD8+ T-cells and Not a Low CD4:CD8 Ratio Predict cytologic HPV-Related Dysplasia in cART-Treated, HIV-Positive Subjects. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac046.	0.4	2
3	Real World Estimate of Vaccination Protection in Individuals Hospitalized for COVID-19. <i>Vaccines</i> , 2022, 10, 550.	2.1	4
4	Role of dalbavancin as combination therapy: evidence from the literature and clinical scenarios. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 997-1004.	2.0	4
5	Enhancing care for people living with HIV: current and future monitoring approaches. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 443-456.	2.0	3
6	Dyslipidaemia after switch to tenofovir alafenamide (TAF)-based cART regimens in a cohort of HIV-positive patients: what clinical relevance?. <i>HIV Medicine</i> , 2021, 22, 140-145.	1.0	12
7	Anxiety and depression symptoms after virological clearance of COVID-19: A cross-sectional study in Milan, Italy. <i>Journal of Medical Virology</i> , 2021, 93, 1175-1179.	2.5	115
8	A 20-year-old girl with an unusual febrile illness. <i>Internal and Emergency Medicine</i> , 2021, , 1.	1.0	0
9	Time spent with HIV-RNA ≥ 200 copies/ml in a cohort of people with HIV during the U=U era. <i>Aids</i> , 2021, 35, 1103-1112.	1.0	15
10	Long-Term Suppressive cART Is Not Sufficient to Restore Intestinal Permeability and Gut Microbiota Compositional Changes. <i>Frontiers in Immunology</i> , 2021, 12, 639291.	2.2	18
11	Plasmacytoid Dendritic Cells Depletion and Elevation of IFN- γ Dependent Chemokines CXCL9 and CXCL10 in Children With Multisystem Inflammatory Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 654587.	2.2	39
12	Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary loss. <i>Scientific Reports</i> , 2021, 11, 9632.	1.6	1
13	Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078 health care workers. <i>EClinicalMedicine</i> , 2021, 36, 100914.	3.2	22
14	Renal microsporidiosis due to <i>Encephalitozoon cuniculi</i> in an HIV/AIDS patient with persistent fever and kidney injury. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1439-1440.	2.8	0
15	Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV. <i>BMC Infectious Diseases</i> , 2021, 21, 557.	1.3	4
16	A Quantitative Estimate of the Expected Shortening of the Median Isolation Period of Patients With COVID-19 After the Adoption of a Symptom-Based Strategy. <i>Frontiers in Public Health</i> , 2021, 9, 639347.	1.3	0
17	Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepalICONA Foundation Cohort Study. <i>Viruses</i> , 2021, 13, 1402.	1.5	4
18	Incidence, Risk Factors and Impact on Clinical Outcomes of Bloodstream Infections in Patients Hospitalised with COVID-19: A Prospective Cohort Study. <i>Antibiotics</i> , 2021, 10, 1031.	1.5	7

#	ARTICLE	IF	CITATIONS
19	Women are from venus: implications for diversified sex-based preexposure prophylaxis approaches. <i>Aids</i> , 2021, 35, 1691-1693.	1.0	0
20	Lack of HIV seroconversion in a patient treated immediately with antiretroviral therapy at acute infection and virus relapse. <i>Aids</i> , 2021, 35, 1708-1710.	1.0	0
21	Predictors of low ovarian reserve in cART-treated women living with HIV. <i>Medicine (United States)</i> , 2021, 100, e27157.	0.4	7
22	Long-term positive effect of an educational antimicrobial stewardship program implemented in an Internal Medicine Department: a prospective analysis and a point prevalence survey on long-term effect. <i>Journal of Chemotherapy</i> , 2021, 33, 238-244.	0.7	2
23	Three case reports of West Nile virus neuroinvasive disease: lessons from real-life clinical practice. <i>BMC Infectious Diseases</i> , 2021, 21, 1132.	1.3	5
24	Do Combination Antiretroviral Therapy Regimens for HIV Infection Feature Diverse T-Cell Phenotypes and Inflammatory Profiles?. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa340.	0.4	8
25	Impact of daily versus weekly service of infectious diseases consultation on hospital antimicrobial consumption: a retrospective study. <i>BMC Infectious Diseases</i> , 2020, 20, 812.	1.3	2
26	Heightened Circulating Interferon-Inducible Chemokines, and Activated Pro-Cytolytic Th1-Cell Phenotype Features Covid-19 Aggravation in the Second Week of Illness. <i>Frontiers in Immunology</i> , 2020, 11, 580987.	2.2	46
27	Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study). <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 1271-1279.	2.0	25
28	Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTiON) cohort. <i>HIV Medicine</i> , 2020, 21, 523-535.	1.0	6
29	Immune response in children with COVID-19 is characterized by lower levels of T-cell activation than infected adults. <i>European Journal of Immunology</i> , 2020, 50, 1412-1414.	1.6	40
30	Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection—Results of Italian Network of ACuTe HIV InfectiON (INACTiON) Retrospective Study. <i>Pathogens and Immunity</i> , 2020, 5, 8.	1.4	16
31	Evaluation of the effect of protective genetic variants on cART success in HIV-1-infected patients. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2020, 34, 1553 -1559.	0.7	3
32	Disseminated cytomegalovirus disease after bendamustine: a case report and analysis of circulating B- and T-cell subsets. <i>BMC Infectious Diseases</i> , 2019, 19, 881.	1.3	10
33	Association Between Impaired V α 7.2+CD161++CD8+ (MAIT) and V α 7.2+CD161-CD8+ T-Cell Populations and Gut Dysbiosis in Chronically HIV- and/or HCV-Infected Patients. <i>Frontiers in Microbiology</i> , 2019, 10, 1972.	1.5	20
34	Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3295-3304.	1.3	14
35	Reduction of Immune Activation and Partial Recovery of Staphylococcal Enterotoxin B-Induced Cytokine Production After Switching to an Integrase Strand Transfer Inhibitor-Containing Regimen: Results from an Observational Cohort Study. <i>Clinical Drug Investigation</i> , 2019, 39, 1239-1249.	1.1	2
36	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. <i>Journal of the International AIDS Society</i> , 2019, 22, e25227.	1.2	46

#	ARTICLE	IF	CITATIONS
37	Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1363-1367.	1.3	21
38	Successful direct-acting antiviral therapy in HIV/HCV co-infected patients fails to restore circulating mucosal-associated invariant T cells. <i>European Journal of Immunology</i> , 2019, 49, 1127-1129.	1.6	13
39	Mucosal cell populations may contribute to peripheral immune abnormalities in HIV-infected subjects introducing cART with moderate immune-suppression. <i>PLoS ONE</i> , 2019, 14, e0212075.	1.1	1
40	Therapeutic Effect of Iron Citrate in Blocking Calcium Deposition in High Pi-Calcified VSMC: Role of Autophagy and Apoptosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5925.	1.8	22
41	Biomarkers of aging in HIV: inflammation and the microbiome. <i>European Geriatric Medicine</i> , 2019, 10, 175-182.	1.2	2
42	Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients. <i>New Microbiologica</i> , 2019, 42, 69-80.	0.1	0
43	T-Cell Subsets (T _H 1, T _H 2, T _H 17) and Poly-Functional Immune Response in Patients with Human Immunodeficiency Virus (HIV) Infection and Different T-CD4 Cell Response. <i>Annals of Clinical and Laboratory Science</i> , 2019, 49, 519-528.	0.2	3
44	Pegylated Interferon- α -Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients. <i>Clinical Infectious Diseases</i> , 2018, 66, 1910-1917.	2.9	30
45	Immune activation, inflammation and HIV DNA after 96-weeks of ATV/r monotherapy: a MODAt substudy. <i>Antiviral Therapy</i> , 2018, 23, 633-637.	0.6	2
46	Unconventional T cells in chronic hepatitis B patients on long-term suppressive therapy with tenofovir followed by a Peg-IFN α addition strategy: A randomized study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 381-390.	1.0	12
47	Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients. <i>HIV Clinical Trials</i> , 2018, 19, 158-162.	2.0	2
48	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3460-3470.	1.3	8
49	Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. <i>BMC Medicine</i> , 2018, 16, 79.	2.3	24
50	Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. <i>BMC Public Health</i> , 2018, 18, 870.	1.2	19
51	Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART). <i>Journal of NeuroVirology</i> , 2018, 24, 679-694.	1.0	3
52	Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature. <i>BMC Infectious Diseases</i> , 2018, 18, 8.	1.3	5
53	The fecal microbiome directly drives immune activation in HIV infection. <i>Annals of Translational Medicine</i> , 2018, 6, S45-S45.	0.7	1
54	Cardiovascular disease in women with HIV-1 infection. <i>International Journal of Cardiology</i> , 2017, 241, 50-56.	0.8	14

#	ARTICLE	IF	CITATIONS
55	Brief Report: Soluble CD163 in CMV-Infected and CMV-Uninfected Subjects on Virologically Suppressive Antiretroviral Therapy in the ICONA Cohort. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 74, 347-352.	0.9	16
56	Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≥ 50 copies/mL. <i>Infection</i> , 2017, 45, 521-528.	2.3	10
57	Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. <i>Clinical Microbiology and Infection</i> , 2017, 23, 267.e1-267.e4.	2.8	11
58	Clinical and viro-immunological correlates of HIV associated neurocognitive disorders (HAND) in a cohort of antiretroviral-naïve HIV-infected patients. <i>Aids</i> , 2017, 31, 311-314.	1.0	5
59	Brief Report: Drop in CD4+ Counts Below 200 Cells/ μ L After Reaching (or Starting From) Values Higher than 350 Cells/ μ L in HIV-Infected Patients With Virological Suppression. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 76, 417-422.	0.9	2
60	Durability of Second Antiretroviral Regimens in the Italian Cohort Naïve Antiretrovirals Foundation Study and Factors Associated with Discontinuation. <i>AIDS Patient Care and STDs</i> , 2017, 31, 487-494.	1.1	7
61	Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 75, 465-471.	0.9	4
62	Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort. <i>PLoS ONE</i> , 2017, 12, e0189045.	1.1	4
63	Novelties in evaluation and monitoring of HIV-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?. <i>AIDS Reviews</i> , 2017, 19, .	0.5	5
64	Stimulation of PBMC and Monocyte-Derived Macrophages via Toll-Like Receptor Activates Innate Immune Pathways in HIV-Infected Patients on Virally Suppressive Combination Antiretroviral Therapy. <i>Frontiers in Immunology</i> , 2016, 7, 614.	2.2	30
65	Discontinuation of Initial Antiretroviral Therapy in Clinical Practice. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 263-271.	0.9	39
66	Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection. <i>AIDS Research and Therapy</i> , 2016, 13, 19.	0.7	105
67	Cell-Mediated Immunity in HIV-Infected Males With Human Papillomavirus-Related Anal Dysplastic Lesions. <i>Clinical Infectious Diseases</i> , 2016, 63, 1396-1398.	2.9	1
68	Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically suppressive combination antiretroviral therapy. <i>Aids</i> , 2016, 30, 991-1003.	1.0	55
69	Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. <i>Clinical Microbiology and Infection</i> , 2016, 22, 288.e1-288.e8.	2.8	33
70	Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. <i>PLoS ONE</i> , 2016, 11, e0160761.	1.1	5
71	Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. <i>PLoS ONE</i> , 2016, 11, e0156360.	1.1	0
72	Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the ICONA Foundation cohort. <i>HIV Medicine</i> , 2015, 16, 412-420.	1.0	4

#	ARTICLE	IF	CITATIONS
73	T-cell phenotype and function following a first cART regimen containing either a protease inhibitor or a non-nucleoside retrotranscriptase inhibitor in HIV-infected late presenters: results from a retrospective, ex vivo study. <i>Antiviral Therapy</i> , 2015, 21, 133-142.	0.6	5
74	Assessment of radiological vertebral fractures in HIV-infected patients: clinical implications and predictive factors. <i>HIV Medicine</i> , 2015, 16, 563-571.	1.0	20
75	Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. <i>PLoS ONE</i> , 2015, 10, e0124252.	1.1	7
76	Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. <i>PLoS ONE</i> , 2015, 10, e0140877.	1.1	7
77	CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. <i>Lancet HIV</i> , 2015, 2, e98-e106.	2.1	249
78	Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. <i>PLoS Medicine</i> , 2015, 12, e1001809.	3.9	119
79	Immunophenotype and Function of CD38-Expressing CD4+ and CD8+ T Cells in HIV-Infected Patients Undergoing Suppressive Combination Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2015, 211, 1511-1513.	1.9	15
80	Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non-AIDS-Defining Events in a Large Cohort of HIV-Infected Patients. <i>Journal of Infectious Diseases</i> , 2015, 211, 178-186.	1.9	146
81	Factors associated with HPV-DNA clearance in a cohort of HIV-positive patients: role of cART and gender. <i>Journal of the International AIDS Society</i> , 2014, 17, 19717.	1.2	1
82	CD4 cell count and the risk of infective and non-infective serious non-AIDS events in HIV-positive persons seen for care in Italy. <i>Journal of the International AIDS Society</i> , 2014, 17, 19509.	1.2	2
83	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3085-3094.	1.3	6
84	Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study. <i>BMC Infectious Diseases</i> , 2014, 14, 79.	1.3	23
85	Efficacy and Safety of Darunavir/Ritonavir Plus Etravirine Dual Regimen in Antiretroviral Therapy-Experienced Patients: A Multicenter Clinical Experience. <i>HIV Clinical Trials</i> , 2014, 15, 140-150.	2.0	10
86	Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 735-741.	1.3	16
87	Highlights on HIV eradication in 2013. <i>Aids</i> , 2014, 28, 1-7.	1.0	5
88	Invariant Natural Killer T (iNKT) Cells in HAART-Treated, HIV-Positive Patients with Bone and Cardiovascular Impairment. <i>PLoS ONE</i> , 2014, 9, e110287.	1.1	6
89	Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients. <i>Journal of Translational Medicine</i> , 2013, 11, 51.	1.8	48
90	Microbial Translocation in the Pathogenesis of HIV Infection and AIDS. <i>Clinical Microbiology Reviews</i> , 2013, 26, 2-18.	5.7	404

#	ARTICLE	IF	CITATIONS
91	CD8 T-Cell Activation Is Associated With Lipodystrophy and Visceral Fat Accumulation in Antiretroviral Therapy-Treated Virologically Suppressed HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 64, 360-366.	0.9	19
92	Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment. <i>Aids</i> , 2013, 27, 769-779.	1.0	70
93	Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. <i>BMC Infectious Diseases</i> , 2013, 13, 471.	1.3	68
94	Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial. <i>PLoS ONE</i> , 2013, 8, e80157.	1.1	35
95	HPV Infection in a Cohort of HIV-Positive Men and Women: Prevalence of Oncogenic Genotypes and Predictors of Mucosal Damage at Genital and Oral Sites. <i>Journal of Sexually Transmitted Diseases</i> , 2013, 2013, 1-8.	1.0	7
96	Role of <i>In Vitro</i> Stimulation with Lipopolysaccharide on T-Cell Activation in HIV-Infected Antiretroviral-Treated Patients. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-9.	3.3	20
97	Reduced Central Memory CD4+ T Cells and Increased T-Cell Activation Characterise Treatment-Naive Patients Newly Diagnosed at Late Stage of HIV Infection. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-10.	0.3	12
98	HIV-Infected Late Presenter Patients. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-2.	0.3	7
99	T-Cell Phenotypes, Apoptosis and Inflammation in HIV+ Patients on Virologically Effective cART with Early Atherosclerosis. <i>PLoS ONE</i> , 2012, 7, e46073.	1.1	61
100	Circulating sCD14 Is Associated with Virological Response to Pegylated-Interferon-Alpha/Ribavirin Treatment in HIV/HCV Co-Infected Patients. <i>PLoS ONE</i> , 2012, 7, e32028.	1.1	34
101	Immune Reconstitution in HIV+ Subjects on Lopinavir/Ritonavir-Based HAART According to the Severity of Pre-Therapy CD4+. <i>Current HIV Research</i> , 2012, 10, 597-605.	0.2	11
102	Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients. <i>Journal of Visualized Experiments</i> , 2011, , .	0.2	4
103	Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. <i>Aids</i> , 2011, 25, 1385-1394.	1.0	155
104	Detrimental Effect of Atazanavir Plasma Concentrations on Total Serum Bilirubin Levels in the Presence of UGT1A1 Polymorphisms. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, e96-e97.	0.9	5
105	Evidence for Polymicrobial Flora Translocating in Peripheral Blood of HIV-Infected Patients with Poor Immune Response to Antiretroviral Therapy. <i>PLoS ONE</i> , 2011, 6, e18580.	1.1	97
106	Reduced CD127 expression on peripheral CD4+ T cells impairs immunological recovery in course of suppressive highly active antiretroviral therapy. <i>Aids</i> , 2010, 24, 2590-2593.	1.0	21
107	Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAART. <i>Aids</i> , 2010, 24, 1455-1460.	1.0	33
108	Increased Bone Marrow Interleukin-7 (IL-7)/IL-7R Levels but Reduced IL-7 Responsiveness in HIV-Positive Patients Lacking CD4+ Gain on Antiviral Therapy. <i>PLoS ONE</i> , 2010, 5, e15663.	1.1	16

#	ARTICLE	IF	CITATIONS
109	Use of the FRAX Equation as First-Line Screening of Bone Metabolism Alteration in the HIV-Infected Population. <i>Journal of Infectious Diseases</i> , 2010, 202, 330-331.	1.9	22
110	Noncirrhotic Portal Hypertension in HIV-Infected Patients: A Case Control Evaluation and Review of the Literature. <i>AIDS Patient Care and STDs</i> , 2010, 24, 697-703.	1.1	19
111	CD4+ T Cell Depletion, Immune Activation and Increased Production of Regulatory T Cells in the Thymus of HIV-Infected Individuals. <i>PLoS ONE</i> , 2010, 5, e10788.	1.1	51
112	Qualitative Immune Modulation by Interleukin-2 (IL-2) Adjuvant Therapy in Immunological Non Responder HIV-Infected Patients. <i>PLoS ONE</i> , 2010, 5, e14119.	1.1	16
113	Immunological Mechanisms of Interleukin-2 (IL-2) Treatment in HIV/AIDS Disease. <i>Current Molecular Pharmacology</i> , 2009, 2, 40-45.	0.7	8
114	The Absence of CD4+ T Cell Count Recovery Despite Receipt of Virologically Suppressive Highly Active Antiretroviral Therapy: Clinical Risk, Immunological Gaps, and Therapeutic Options. <i>Clinical Infectious Diseases</i> , 2009, 48, 328-337.	2.9	150
115	The Absence of CD4+ T Cell Count Recovery Despite Receipt of Virologically Suppressive Highly Active Antiretroviral Therapy: Clinical Risk, Immunological Gaps, and Therapeutic Options. <i>Clinical Infectious Diseases</i> , 2009, 48, 328-337.	2.9	163
116	Does fluvastatin favour HCV replication <i>in vivo</i> ? A pilot study on HIV-HCV coinfecting patients. <i>Journal of Viral Hepatitis</i> , 2009, 16, 479-484.	1.0	36
117	HIV-infected long-term nonprogressors display a unique correlative pattern between the interleukin-7/interleukin-7 receptor circuit and T-cell homeostasis. <i>HIV Medicine</i> , 2009, 10, 422-431.	1.0	11
118	CD8+ Hyperactivation and Senescence Correlate With Early Carotid Intima-Media Thickness in HIV+ Patients With No Cardiovascular Disease. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 642-644.	0.9	18
119	Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection. <i>Antiviral Therapy</i> , 2009, 14, 321-330.	0.6	41
120	Untangling the Immunological Implications of Nadir on CD4+ Cell Recovery during Suppressive Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2008, 46, 149-150.	2.9	7
121	<i>Rhodococcus equi</i> infection in a patient with spinocellular carcinoma of unknown origin. <i>Journal of Medical Microbiology</i> , 2008, 57, 1431-1433.	0.7	6
122	Early Impairment of Gut Function and Gut Flora Supporting a Role for Alteration of Gastrointestinal Mucosa in Human Immunodeficiency Virus Pathogenesis. <i>Journal of Clinical Microbiology</i> , 2008, 46, 757-758.	1.8	191
123	Abacavir and Cardiovascular Risk in HIV-Infected Patients: Does T Lymphocyte Hyperactivation Exert a Pathogenic Role?. <i>Clinical Infectious Diseases</i> , 2008, 47, 1495-1496.	2.9	6
124	The Challenge of IL-2 Immunotherapy in HIV Disease: 'No through Road' or Turning Point?. <i>Current HIV Research</i> , 2008, 6, 189-199.	0.2	7
125	Sudden Cardiac Death in a Young HIV-Positive Man on Effective Antiretroviral Therapy. <i>Current HIV Research</i> , 2008, 6, 560-562.	0.2	1
126	Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. <i>Aids</i> , 2008, 22, 2035-2038.	1.0	256

#	ARTICLE	IF	CITATIONS
127	Serum β -Fetoprotein Levels Predict Early Virologic Response in HIV-Positive Subjects Treated for Chronic Hepatitis C. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 361-363.	0.9	1
128	Effective nocturnal oxygen therapy increases circulating level of tumor necrosis factor- β in heart failure. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 64-67.	0.6	0
129	Fully Immunocompetent CD8+ T Lymphocytes Are Present in Autologous Haematopoietic Stem Cell Transplantation Recipients Despite an Ineffectual T-Helper Response. <i>PLoS ONE</i> , 2008, 3, e3616.	1.1	4
130	Successful Rescue Therapy with a Darunavir/Ritonavir and Etravirine Antiretroviral Regimen in a Child with Vertically Acquired Multidrug-Resistant HIV-1. <i>Antiviral Therapy</i> , 2008, 13, 839-843.	0.6	15
131	Nosocomial Bacterial Pneumonia in HIV-Infected Patients: Risk Factors for Adverse Outcome and Implications for Rational Empiric Antibiotic Therapy. <i>Infection</i> , 2006, 34, 9-16.	2.3	57
132	Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. <i>Aids</i> , 2006, 20, 1727-1736.	1.0	127
133	Spoligotyping and <i>Mycobacterium tuberculosis</i> . <i>Emerging Infectious Diseases</i> , 2005, 11, 1242-1248.	2.0	80
134	Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap?. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 401-409.	1.3	34
135	Immunomodulants in HIV infection. <i>Expert Opinion on Therapeutic Patents</i> , 2005, 15, 1115-1131.	2.4	1
136	Comparison between spoligotyping and IS6110 restriction fragment length polymorphisms in molecular genotyping analysis of <i>Mycobacterium tuberculosis</i> strains. <i>Molecular and Cellular Probes</i> , 2005, 19, 236-244.	0.9	23
137	Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics. <i>Aids</i> , 2004, 18, 211-216.	1.0	22
138	IL-7/IL-7 receptor system regulation following IL-2 immunotherapy in HIV-infected patients. <i>Antiviral Therapy</i> , 2004, 9, 447-52.	0.6	1
139	Immunomodulation induced by tucaresol in HIV infection: results of a 16 week pilot Phase I/II trial. <i>Antiviral Therapy</i> , 2004, 9, 603-14.	0.6	3
140	IL-7/IL-7 Receptor System Regulation following IL-2 Immunotherapy in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2004, 9, 447-452.	0.6	12
141	Immunomodulation Induced by Tucaresol in HIV Infection: Results of a 16 Week Pilot Phase I/II Trial. <i>Antiviral Therapy</i> , 2004, 9, 603-614.	0.6	13
142	Delayed-Type Hypersensitivity Skin Testing Can Predict CD4 Count Increase in HIV Patients With Poor Immunologic Response to HAART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 277-278.	0.9	2
143	Low-Dose Prolonged Intermittent Interleukin-2 Adjuvant Therapy: Results of a Randomized Trial among Human Immunodeficiency Virus-Positive Patients with Advanced Immune Impairment. <i>Journal of Infectious Diseases</i> , 2002, 186, 606-616.	1.9	63
144	PCR-Hybridization Assay for <i>Mycobacterium avium</i> Complex: Optimization of Detection in Peripheral Blood from Humans. <i>Journal of Clinical Microbiology</i> , 2001, 39, 1638-1643.	1.8	6

#	ARTICLE	IF	CITATIONS
145	Molecular Epidemiology Study of Exogenous Reinfection in an Area with a Low Incidence of Tuberculosis. <i>Journal of Clinical Microbiology</i> , 2001, 39, 2213-2218.	1.8	123
146	Detection of T cell receptor circles (TRECs) as biomarkers for de novo T cell synthesis using a quantitative polymerase chain reaction-enzyme linked immunosorbent assay (PCR-ELISA). <i>Journal of Immunological Methods</i> , 2000, 237, 187-197.	0.6	78
147	A Case of Costochondral Abscess due to <i>Corynebacterium minutissimum</i> in an HIV-infected Patient. <i>Journal of Infection</i> , 2000, 41, 103-105.	1.7	28
148	Tumor Necrosis Factor- γ Increased Production during Thalidomide Treatment in Patients with Tuberculosis and Human Immunodeficiency Virus Coinfection. <i>Journal of Infectious Diseases</i> , 2000, 182, 639-639.	1.9	13
149	Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease. <i>Aids</i> , 2000, 14, 1859-1861.	1.0	10
150	A PCR-Colorimetric Microwell Plate Hybridization Assay for Detection of <i>Mycobacterium tuberculosis</i> and <i>M. avium</i> from Culture Samples and Ziehl-Neelsen-Positive Smears. <i>Journal of Clinical Microbiology</i> , 2000, 38, 1772-1776.	1.8	18
151	A case of Austrian's syndrome with ocular involvement. <i>Infection</i> , 1999, 27, 46-47.	2.3	31
152	The human thymus: A new perspective on thymic function, aging, and hiv infection. <i>Clinical Immunology Newsletter</i> , 1999, 19, 65-79.	0.1	8
153	Monitoring of Transmission of Tuberculosis between Wild Boars and Cattle: Genotypical Analysis of Strains by Molecular Epidemiology Techniques. <i>Journal of Clinical Microbiology</i> , 1999, 37, 2766-2771.	1.8	98
154	Mediterranean leishmaniasis in HIV-infected patients: Epidemiological, clinical, and diagnostic features of 22 cases. <i>Infection</i> , 1998, 26, 93-99.	2.3	40
155	Clinical and Immunological Improvement in a Patient Who Received Thalidomide Treatment for Refractory <i>Mycobacterium avium</i> Complex Infection. <i>Clinical Infectious Diseases</i> , 1998, 26, 184-185.	2.9	10
156	Nested Polymerase Chain Reaction for <i>Mycobacterium tuberculosis</i> IS6110 Sequence on Formalin-Fixed Paraffin-Embedded Tissues With Granulomatous Diseases for Rapid Diagnosis of Tuberculosis. <i>American Journal of Clinical Pathology</i> , 1998, 109, 411-415.	0.4	37
157	Evaluation of PCR in Detection of <i>Mycobacterium tuberculosis</i> from Formalin-Fixed, Paraffin-Embedded Tissues: Comparison of Four Amplification Assays. <i>Journal of Clinical Microbiology</i> , 1998, 36, 1512-1517.	1.8	111
158	Molecular epidemiology characterization of a multidrug-resistant <i>Mycobacterium bovis</i> outbreak amongst HIV-positive patients. <i>Aids</i> , 1998, 12, 445-6.	1.0	10
159	Cutaneous Infection Caused by <i>Mycobacterium gordonae</i> in a Human Immunodeficiency Virus-Infected Patient Receiving Antimycobacterial Treatment. <i>Clinical Infectious Diseases</i> , 1997, 25, 1490-1491.	2.9	17
160	Use of multiplex PCR assay and DNA fingerprinting analysis for typing of multidrug-resistant <i>Mycobacterium tuberculosis</i> strains. <i>Journal of Infection</i> , 1997, 35, 322-323.	1.7	0
161	Specific detection of <i>Mycobacterium tuberculosis</i> by mtp40 nested PCR. <i>Journal of Clinical Microbiology</i> , 1996, 34, 2866-2867.	1.8	13
162	Effectiveness Of Aminosidine (Paromomycin) Sulfate In Chronic <i>Cryptosporidium</i> Diarrhea In Aids Patients: An Open, Uncontrolled, Prospective Clinical Trial. <i>Journal of Infectious Diseases</i> , 1994, 170, 1349-1350.	1.9	38

#	ARTICLE	IF	CITATIONS
163	SARS-CoV-2 and the nervous system: review on pathogenesis of nervous system SARS-CoV-2 damage. , 0, , ·		1
164	Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors. Frontiers in Immunology, 0, 13, .	2.2	10